Botox® vs Xeomin® vs Dysport®: Key Differences Explained

Botox®, Xeomin®, and Dysport® are all botulinum toxin type A injectables. They come from the same bacterium, work through the same mechanism, and treat many of the same conditions. Ask most injectors which one they prefer and you’ll get an answer rooted in habit and purchasing contracts as much as pharmacology.

The three products are not interchangeable, though — and one difference is a genuine patient-safety issue rather than a matter of preference. Units do not convert one-to-one across brands. A clinician who carries Botox dosing habits into a Dysport vial is not making a stylistic choice; they are making a dosing error.

This guide covers what actually separates Botox, Xeomin, and Dysport — composition, onset, duration, diffusion, dosing conversion, immunogenicity, cost, and best use cases — and where the differences are smaller than the marketing suggests.

The Common Ground: What All Three Share

Every FDA-approved botulinum toxin type A product on the U.S. market is produced by fermentation of the Hall strain of Clostridium botulinum, serotype A. All of them bind to acceptor sites on motor and sympathetic nerve terminals, block acetylcholine release, and relax the target muscle. The underlying mechanism of botulinum toxin is identical across brands.

All three are:

• Delivered by intramuscular injection into mapped points
• Temporary, requiring repeat treatment
• Measured in units of biological potency rather than milligrams — each manufacturer’s unit defined by its own assay
• Effective for dynamic wrinkles, and largely ineffective against static lines from sun damage and volume loss
• FDA-approved as safe and effective for their labeled indications

One structural point deserves bluntness: there will never be a definitive head-to-head trial declaring one product superior across the board. Each preparation is a distinct biologic with its own potency assay, so they cannot be compared on a shared unit scale. Claims that one brand is simply “better” are opinion, not evidence.

Composition and Molecular Structure

The real chemistry differences come down to three things: the accessory (complexing) proteins around the toxin, the complex molecular weight, and the excipients used to stabilize the product.

Botox (onabotulinumtoxinA)

Manufactured by Allergan, Botox is the reference product — the one every other neuromodulator is described against. It is isolated by dialysis and acid precipitation, has a complex molecular weight of roughly 900 kDa, and is stabilized with human albumin and 0.9% sodium chloride. It is vacuum-dried and requires refrigeration before reconstitution. The vial carries approximately 5 ng of neurotoxin protein.

Xeomin (incobotulinumtoxinA)

Produced by Merz and branded Bocouture® outside the United States, Xeomin uses the same Hall strain and the same dialysis/acid-precipitation isolation as Botox, but strips away the accessory proteins. This is the origin of its nickname: the “naked” toxin. Its complex molecular weight is roughly 200–300 kDa. It is lyophilized and stabilized with human albumin and sucrose.

The absence of complexing proteins drives Xeomin’s two distinguishing practical claims: a theoretically lower immunogenic load, and no refrigeration requirement prior to reconstitution.

Dysport (abobotulinumtoxinA)

Dysport uses the NCTC 2916 (Hall) strain and is isolated by acid precipitation plus column chromatography. Its complex molecular weight spans roughly 500–900 kDa, and it is described as containing smaller molecular complexes than Botox. It is lyophilized, stabilized with human albumin and lactose, and carries approximately 12.5 ng of neurotoxin protein per vial — a meaningfully higher protein load than Botox.

Both Botox and Dysport contain complexing proteins. Xeomin does not. Beyond molecular weight, protein content, and excipient, the products are pharmacologically very similar.

Jeuveau and Daxxify

Two newer entrants round out the category. Jeuveau® (prabotulinumtoxinA) has a complex molecular weight identical to Botox, making dose calculation intuitive for clinicians already fluent in Botox units. Daxxify® (daxibotulinumtoxinA) is the most recent addition. Both are botulinum toxin type A, but Botox, Xeomin, and Dysport remain the three products most clinicians actually stock.

Dosing and Unit Conversion — The Point That Matters Most

If you take one thing from this article, take this: units are not interchangeable between brands. A Botox unit, a Xeomin unit, and a Dysport unit are each defined by their manufacturer’s own potency assay. They are not a shared currency.

The conventions clinicians work with:

• Xeomin to Botox — generally considered roughly 1:1. Most injectors treat the two as substitutable on a unit-for-unit basis, though individual response still varies.
• Dysport to Botox — commonly dosed at roughly 2.5:1 to 3:1. Approximately 2.5 to 3 Dysport units are used where 1 Botox unit would be.

Treat those as widely used conventions, not as absolute rules. Ratios reported in the literature and used in practice vary by treatment area, muscle mass, dilution, and injector. They are a starting point for judgment, not a substitute for it.

The failure mode here is not theoretical. An injector who reaches for Dysport and reflexively dials in a Botox-sized number of units has under-dosed by roughly two-thirds. Run the error the other direction — Dysport-sized numbers drawn from a Botox vial — and you have a substantial overdose in a facial muscle group, with diffusion, ptosis, and prolonged dysfunction as the likely consequences.

Dilution adds a second layer of care. Botox and Xeomin both come in 50- and 100-unit packages; reconstitution volume determines final concentration, and concentration interacts with diffusion. Two injectors using the same product at different dilutions are, functionally, using different tools.

Onset: How Fast Do They Work?

All three products act within days, not hours, and none of them show full effect immediately.

• Botox — onset commonly described in the range of two to five days, with full effect over roughly one to two weeks.
• Xeomin — often described as taking slightly longer, in the range of three to seven days, though this is patient- and context-dependent. Some clinicians and some studies report the opposite. The honest summary is that the difference, if it exists, is small.
• Dysport — frequently reported as the fastest of the three, with some patients noticing change within one to two days.

One theory attributes Dysport’s faster perceived onset to its smaller molecular complexes. It is a plausible explanation and a commonly repeated one, but it remains a hypothesis rather than settled science. Onset is also heavily influenced by dose, dilution, muscle mass, and how closely the patient is watching the mirror. Our guide on how long Botox takes to work covers the full timeline in detail.

Duration: Which Lasts Longer?

This is where the marketing noise most outruns the evidence. For cosmetic use, all three products land in a comparable range — commonly cited as three to six months, depending on dose, treatment area, and individual patient factors.

Clinical research has not established a meaningful durability advantage for any one of the three. Individual experience varies with metabolism, muscle mass, dose, and treatment history, which is why patients often swear one product lasted longer for them. That is real data about that patient, not evidence about the product. If a patient reports that a product faded early, the more productive investigation is dose and placement, not brand.

Diffusion and Spread

Diffusion — how far the toxin migrates from the injection point — is one of the few differences with consistent clinical consequences.

• Botox has a moderate, predictable diffusion profile, which supports precise targeting of individual muscles.
• Dysport is generally described as having greater spread. This can be an advantage or a liability depending on what you’re treating.
• Xeomin behaves comparably to Botox in practice. Its “naked” formulation was initially thought to potentially increase spread; clinical experience has not borne that out. At comparable dilution, some clinicians observe that Xeomin diffuses somewhat farther, which would suit larger muscle groups — another reminder that dilution, not just brand, drives spread.

Greater diffusion means Dysport may cover a broad area like the frontalis with fewer injection points. It also means less margin for error near structures you do not want to relax. Botox and Xeomin are often preferred where containment matters — crow’s feet, a subtle brow lift, work near the levator palpebrae. Diffusion into the wrong muscle is the mechanism behind most cases of eyelid ptosis, and it is a technique problem before it is a product problem. See our Botox injection sites guide for area-by-area mapping.

Immunogenicity and Resistance

Repeated exposure to any biologic can, in principle, provoke neutralizing antibodies that reduce or eliminate response over time. True secondary non-response to botulinum toxin is uncommon, but it happens.

Xeomin’s lower protein load is the basis of its lower-immunogenicity argument: fewer foreign proteins introduced means, in theory, less to react against. It is mechanistically sensible, and it is why Xeomin is often the product of choice for patients who appear to have stopped responding to another toxin. But it should be presented as what it is — this advantage has not been proven in clinical practice, and more study is needed. Do not sell a patient on Xeomin as guaranteed insurance against resistance.

Cost

Per-unit price comparison across brands is close to meaningless without accounting for the conversion ratio.

Botox and Xeomin sit in broadly similar per-unit territory, with Xeomin sometimes priced slightly lower. Dysport typically carries a noticeably lower per-unit cost — but because it is less concentrated and requires roughly 2.5 to 3 times as many units, the total cost of a comparable treatment often lands in the same neighborhood. A patient quoted a low per-unit Dysport price and a high per-unit Botox price is not being told the whole story unless the unit counts come with it.

Actual pricing varies substantially by geography, provider, treatment area, and purchasing agreements. Patients should compare total treatment cost, not unit price — and injectors should explain that distinction rather than exploit the confusion, ideally during the consultation.

Indications: What Each Is Approved For

Botox has by far the broadest set of FDA-approved indications. It was approved for human testing in 1978 as “oculinum,” received its first FDA approvals in 1989 for strabismus and blepharospasm, and was renamed onabotulinumtoxinA in 1991. Cosmetic approval for glabellar lines followed in 2002, with lateral canthal rhytids in 2013 and forehead rhytids in 2017. Therapeutic approvals include cervical dystonia (2000), chronic migraine (2010–2012), and overactive bladder (2015). It is marketed in two formulations: Botox Cosmetic and Botox Therapeutic.

Dysport received FDA approval for cosmetic use in 2009, covering cervical dystonia and glabellar lines.

Xeomin was approved in the U.S. in 2010 for cervical dystonia, with cosmetic approval for glabellar lines following in 2011, plus subsequent approvals for muscle spasticity, blepharospasm, and hemifacial spasm. Its approved range remains narrower than Botox’s.

Because all three share an active ingredient, all three are used off-label for overlapping purposes — masseter hypertrophy and bruxism, gummy smile, platysmal bands, and more. Off-label use is legal and common, but it should be documented and consented as such.

Head to Head: Choosing Between Botox, Xeomin, and Dysport

There is a defensible argument for each:

• Choose Botox when you want the deepest track record, the broadest label, and the most predictable diffusion for precise work in small or high-risk areas. It is also the product most patients recognize and ask for by name.
• Choose Xeomin when a patient appears to have developed resistance to another toxin, when minimizing protein load is a priority, or when storage logistics matter — no refrigeration before reconstitution is a genuine convenience for lower-overhead practices and for anyone trialing a new product without committing cold-chain space.
• Choose Dysport for larger surface areas like the forehead where broader spread is an asset rather than a hazard, for patients who want faster visible onset, and where fewer injection points per area is desirable.

For forehead lines specifically, all three work well and technique dominates the outcome. Dysport’s spread suits the broad frontalis; Botox and Xeomin offer tighter control near the brow, where over-relaxation produces heaviness — and where a dosing error stays visible for three months.

Contraindications and Exclusion Criteria

All three products share essentially the same exclusion criteria. Patients should not be treated if they have:

• An “at-risk” neuromuscular condition requiring medical monitoring, such as myasthenia gravis or Lambert-Eaton syndrome
• Certain chronic conditions, including diabetes, rheumatoid arthritis, or congestive heart failure, warranting careful evaluation
• Known allergy or sensitivity to any component — the toxin itself, human albumin, sucrose, or lactose. Note that the excipients differ by brand, which occasionally matters
• Marked facial asymmetry, ptosis, or other anatomical defects
• A known history of facial palsy
• Skin infection at or near the planned injection site
• Known or planned pregnancy, or current breastfeeding

Certain medications also warrant exclusion or caution: anticoagulants such as warfarin, aminoglycoside antibiotics, muscle relaxants and other agents that may potentiate the toxin, and drugs that interfere with or neutralize its action at the muscle.

There is no upper age limit above which botulinum toxin is contraindicated, but older patients carry a higher likelihood of medical contraindications, and their goals should be weighed against known risks accordingly.

Side Effects and Safety

The safety profiles of Botox, Xeomin, and Dysport are broadly similar. Common, self-limiting effects include injection-site pain, bruising, swelling, redness, and itching, along with headache and transient flu-like symptoms. Technique-dependent effects include eyelid drooping, crooked smile, excessive drooling, and dry or teary eyes.

More serious effects that may indicate systemic diffusion — muscle weakness, vision problems, difficulty breathing, difficulty speaking or swallowing, loss of bladder control — are rare but demand immediate evaluation. Observe patients after treatment regardless of which product is in the syringe.

Frequently Asked Questions

Which lasts longer, Botox or Dysport?

Neither has an established durability advantage. Both typically last in the range of three to six months for cosmetic treatment, with individual variation driven by dose, treatment area, muscle mass, and metabolism. Patients who report one lasting longer are reporting a real personal experience, but clinical research has not shown a consistent difference between them.

Is Dysport cheaper than Botox?

Per unit, usually yes — often substantially. Per treatment, usually not. Dysport is less concentrated and requires roughly 2.5 to 3 times as many units to achieve a comparable effect, so total treatment cost frequently lands close to Botox. Compare full treatment quotes, not unit prices.

What is the conversion ratio between Botox and Dysport?

Roughly 2.5:1 to 3:1 Dysport units to Botox units is the conventional range. This is a convention rather than a fixed rule — the appropriate ratio shifts with treatment area, muscle mass, and dilution, and reported ratios vary. Never convert reflexively; the units of these two products are defined by separate potency assays and are not interchangeable.

Does Xeomin work faster than Botox?

Generally, no. Xeomin is often described as taking slightly longer to show effect — roughly three to seven days versus two to five for Botox — though some clinicians and patients report the opposite, and the difference is small and highly patient-dependent. Dysport is the product most frequently described as fastest.

Can you switch between neurotoxins?

Yes, and it is common. The critical requirement is recalculating the dose for the new product rather than carrying over the previous brand’s unit count. Switching to Xeomin is a standard approach for patients who appear to have stopped responding to another toxin. Patients switching products should be counseled that onset and spread may feel slightly different even when the result is equivalent.

Which is better for forehead lines?

All three are effective, and technique matters more than product choice. Dysport’s greater spread can cover the broad frontalis with fewer injection points. Botox and Xeomin offer more contained diffusion, which is useful near the brow where over-relaxation causes heaviness. The right answer depends on the patient’s anatomy and the injector’s familiarity with the product.

What is the difference between Botox, Xeomin, and Dysport?

All three are botulinum toxin type A produced from the Hall strain of C. botulinum, and all work by the same mechanism. The differences are complex molecular weight, neurotoxin protein content, and excipient. Botox (900 kDa, albumin and sodium chloride) is the reference product. Xeomin (200–300 kDa, albumin and sucrose) has the complexing proteins removed and needs no refrigeration before reconstitution. Dysport (500–900 kDa, albumin and lactose) has smaller molecular complexes, greater spread, and requires roughly 2.5 to 3 times as many units as Botox.

Do I need to keep Xeomin refrigerated?

Not before reconstitution — this is one of Xeomin’s clearest practical advantages over Botox and Dysport, which do require refrigeration. It lowers the barrier for practices with limited cold storage and makes trialing the product straightforward.

Learn to Inject All Three Safely

The differences between Botox, Xeomin, and Dysport are real, but second-order. First-order is whether the person holding the syringe understands facial anatomy, can dose accurately for the muscle in front of them, can convert units without hesitation, and knows how to manage a complication. Product choice is preference. Competence is not.

Empire Medical Training has trained physicians, dentists, nurse practitioners, PAs, and registered nurses in aesthetic medicine since 1998. Our Botox Training & Certification course is CME-accredited and hands-on, covering all major neuromodulators, unit conversion, dilution, injection technique, and complication management — with live-patient injection under expert supervision.

Share This Article